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Ampelopsis sinica root is widely used in Chinese folk medicine for treating liver disorders caused by the hepatitis B virus (HBV).
The present study was performed in order to investigate the anti-HBV activity and mechanisms of the ethanol extract from A.
sinica root (EASR) in vitro. The antiviral activity of EASR was examined by detecting the levels ofHBsAg, HBeAg and extracellular
HBV DNAs in stable HBV-producing human hepatoblastoma HepG2 2.2.15 cells. We found that EASR eﬀectively suppressed
the secretion of HBsAg and HBeAg from HepG2 2.2.15 cells in a dose-dependent manner, and it also suppressed the amount of
extracellular HBV DNA. After EASR treatment, the percentage of apoptotic cells was found to be signiﬁcantly higher than that of
control by ﬂow cytometric analysis. A luciferase reporter gene assay was used to determine the eﬀects of EASR on the activities
of HBV promoters and intracellular signaling pathways. The results showed that EASR selectively inhibited the activities of HBV
promoters (Cp, S1p and Fp) and the p53 signalingpathway in HepG2 cells signiﬁcantly. These data indicate that EASR exerts anti-
HBV eﬀects via inhibition of HBV promoters and the p53-associated signaling pathway, which helps to elucidate the mechanism
underlying the potential therapeutic value of EASR.
1.Introduction
The hepatitis B virus (HBV), a member of the Hepadnaviri-
dae family, contains a partial double-stranded circular DNA
genome of 3.2 kb. Its genome has a compact organization,
with four overlapping reading frames running in one
direction and no non-coding regions. This unconventional
genome structure reﬂects the unconventional mode of its
replication, which involves reverse transcription of an RNA
pregenomeof3.5kbasaﬁrststep[1].ThepromotersofHBV
and two enhancers play important roles in the regulation of
viral gene transcription.
Despite the availability of an eﬀective vaccine, the HBV
infection remains a serious global health problem. Chronic
infection of HBV can result in cirrhosis and hepatocellular
carcinoma (HCC), either of which can lead to a liver-related
death[2].Atpresent,severalantiviral drugs,includingIFN-α
and nucleotide analogs, are used to treat chronic hepatitis B.
Nevertheless, their eﬃcacies and serious side eﬀects are still
unsatisfactory [3]. In light of these facts, it is evident that
searching for novel eﬀective antiviral agents is an important
undertaking.
Chinese medicinal herbs have been used to treat liver
disease for centuries [4, 5]. Ampelopsis, a member of the
Vitaceae family, which is distributed in tropical and sub-
tropical regions, is used for treating liver disorders caused by
HBVinChinesefolkmedicine.Previousstudiesdocumented
that the extract of Ampelopsis has hepatoprotective activity,
antioxidative activity, and so forth [6–9]. However, the anti-
HBV activity of the extract of Ampelopsis has not been inves-
tigated.Inthisstudy,weinvestigatedtheantiviralactivityand2 Evidence-Based Complementary and Alternative Medicine
mechanisms of the ethanol extract from Ampelopsis sinica
root (EASR) in vitro.
2.Methods
2.1. EASR and 3TC. Ampelopsis sinica root was collected in
August 2006 from Macheng County, Huhei Province, China.
Specimens of the plant were stored in the herbarium, Hubei
College of Chinese Traditional Medicine, China. The EASR
used in this study was supplied by the Faculty of pharmacy,
Hubei College of Traditional Chinese Medicine, China, and
the extraction procedure has been previously described [6].
Before beginning the experiment, the EASR was dissolved in
distilled water and then diluted with culture medium to the
desired working concentration. Lamivudine (3TC), obtained
from GlaxoSmithKline (Research Triangle Park, NC, USA),
w a su s e da st h ep o s i t i v ec o n t r o l .
2.2. Cell Cultures. HepG2 and HepG2 2.2.15 were pro-
cured from China Center for Typical Culture Collection
(CCTCC) (Wuhan, China). Cells were cultured at 37◦Ci n
a humidiﬁed 5% CO2 atmosphere in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) supplemented with 10% (vol/vol)
FBS, 100UmL−1 penicillin G, 100μgmL −1 streptomycin
(GIBCO, Grand Island, NY, USA). Cells were subcul-
tured every 3 days by detaching the cells with pancreatin
(0.5mgmL−1). The medium was changed on the following
day.
2.3. Cytotoxicity Assays. Cells were seeded in 96-well culture
plates at a density of 1 × 104 cells per well and cultured
at 37◦C for 24h. Then the culture medium was removed
and replaced with fresh medium supplemented with various
concentrations of EASR every other day. After 9 days of
culture, the cytotoxic eﬀect of EASR was evaluated by MTT
assay. Four hours prior to termination of the cultures, 20μL
MTT(5mgmL−1 inaphosphatebuﬀeredsaline,pH7.4)was
added to the monolayer of cells. After incubation at 37◦Cf o r
4h, 150μL DMSO was added to each well to solubilize the
formazan. The opticaldensity (OD)at490nm was measured
by using an automatic plate reader (BIOTek, Elx800).
2.4. Determination of HBsAg and HBeAg. The HepG2 2.2.15
cells were plated at a density of 1 × 104 cells per well on 96-
well cell culture plates and were routinely cultured. Diﬀerent
concentrations of EASR were supplemented to the medium
in triplicate 48h after cells were plated. After incubation
w i t hE A S Rf o r3 ,5 ,7a n d9d a y s ,t h es u p e r n a t a n t sw e r e
collected. The samples were centrifuged at 5000 r min−1 for
10min to drop cellular debris, and then immediately used
for HBsAg or HBeAg assay. The concentrations of HBsAg
and HBeAgwere quantiﬁedby commercial ELISAkit(Kehua
Bio-engineering Corporation, Shanghai, China) according
to the manufacturer’s protocol. Data were calculated as
percentage of control by the formula: (% of control) =
(ODT)/(ODC) × 100%, where ODT and ODC indicated the
cell number adjusted OD of the test drugs and the control,
respectively.
2.5. Determination of HBV DNA. The quantity of extracellu-
lar HBV DNA in the supernatant was detected by real-time
PCR (ABI PRISM 7300 Sequence Detector, PE Biosystems)
based on the TaqMan technology. Viral DNA was extracted
from the culture supernatant and the amount of hepatitis B
viral DNA was quantiﬁed using a diagnostic kit (DaAn Gene
Co. Ltd., Guangzhou, China). A series dilution of known
amounts of HBV DNA was used as a control. The cycling
program was: 93◦C for 2 min, 10 cycles of 93◦Cf o r4 5sa n d
55◦C for 60s, 30 cycles of 93◦C for 30s and 55◦Cf o r4 5s .
2.6. Annexin V/Propidium Iodide Staining for Apoptotic Cells.
The HepG2 2.2.15 cells were plated at a density of 3 ×
105 cells per well on six-well cell culture plates and were
routinely cultured. EASR (40μgmL −1) was supplemented to
the medium in triplicate 48h after cells were plated. After
incubation with EASR for 48h, the cells were harvested.
Cells were then washed and stained with annexin V-
FITC/propidium iodide (PI) as directed by the apopto-
sis detection kit (Kaiji Biotechnology Company, Nanjing,
China). Stained cells were kept at 4◦Ca n dp r o t e c t e df r o m
light until analysis on the ﬂow cytometer.
2.7. Plasmid Constructions and HBV Promoter Luciferase
Reporter Assay. There are ﬁve HBV promoters concerned
in our study—Core promoter (Cp) (nucleotides (nt) 1603–
1819 on GenBank accession no. U95551), S1 promoter
(S1p) (nt 2700–2830), S2 promoter (S2p) (nt 2950–3174),
X promoter (Xp) (nt 935–1361) and full-length promoter
(Fp) (nt 123–1875) [10, 11]. The promoters were ampliﬁed
by PCR from HepG2 2.2.15 cell genomes that contain HBV
genome(U95551,aywsubtype).To generatepCp-Luc,pS1p-
Luc, pS2p-Luc, pXp-Luc and pFp-Luc, the promoter regions
of HBV were cloned upstream of the luciferase reporter
gene of pGL3-basic (Promega, USA), respectively. The
HepG2 cells were transiently transfected with the reporter
vector using Sofast transfection reagent (Xiamen Sunma
Biotechnology, China). After 8h of transfection, cells were
treated with 40μgmL −1 EASR for 48h. The transfected cells
were collected and lysed in order to perform a luciferase
activity assay. HBV promoter activities were determined by
measuring luciferase activity in a TD-20/20 luminometer
(Turner BioSystems, USA) using the Luciferase Reporter
Assay System (Promega, USA).
2.8. Intracellular Signal Transduction Pathway Luciferase
Reporter Assay. PathDetect Cis-/Trans-Reporting Systems
(pNF-κB-Luc, pAP-1-Luc, pISRE-Luc, p53-Luc, pFA2-Elk1,
pFA2-cJun, pFA2-CHOP and pFR-Luc) were obtained from
Stratagene (CA, USA). HepG2 cells were transiently trans-
fected with pNFκB-Luc, pAP-1-Luc, pISRE-Luc, p53-Luc,
pFA2-Elk1 plus pFR-Luc, pFA2-cJun plus pFR-Luc and
pFA2-CHOP plus pFR-Luc using the Sofast transfection
reagent, respectively. After 8h of transfection, cells were
treated with 40μgmL −1 EASR for 48h. The activity of
each signaling pathway was determined by measuring the
luciferase activities of the reporter in treated and untreated
transfectants.Evidence-Based Complementary and Alternative Medicine 3
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Figure 1: The cytotoxicity of EASR on HepG2 and HepG2 2.2.15
cells. The cell viability was evaluated by MTT assay. The data are
presented asmeans ± SD (n = 3).(a) HepG2, and (b) HepG2 2.2.15
cells.
2.9. Statistical Analysis. Statistical analysis was performed
using the SPSS 12.0 software (SPSS Inc., Chicago, IL, USA).
Data were expressed as means ± SD. Student’s t-test and
one-way ANOVA were used to determine the statistical
signiﬁcance of diﬀerences between the test samples and
control. A P < .05 was considered statistically signiﬁcant.
3.Results
3.1. Cytotoxicity of EASR. The cytotoxicity of EASR on the
cell viability of HepG2 2.2.15 cells and HepG2 cells was eval-
uated by using the MTT assay. As shown in Figure 1,t h e r e
was no signiﬁcant diﬀerence of cell viability between EASR-
treatedgroupswhose concentrationswere <200μgmL −1 and
the control group. But higher concentrations of EASR were
demonstrated to be cytotoxic.
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Figure 2: The eﬀect of EASR on HBsAg and HBeAg secretion
in vitro. The cells were cultured with diﬀerent concentrations of
EASR (1.6, 8, 40 and 200mgmL−1) or 3TC at 200mgmL−1 for
3, 5, 7 and 9 days. The concentrations of HBsAg and HBeAg in
culture supernatants were quantiﬁed by ELISA assay. The results
revealed that EASR could inhibit HBsAg and HBeAg secretion dose
dependently in HepG2 2.2.15 cells. The data are presented as means
± SD (n = 3). ∗P < .05 as compared with the no drug group. (a)
HBsAg and (b) HBeAg.
3.2. Anti-HBV Activity of EASR. The HBsAg and HBeAg in
the supernatant were determined by ELISA assay. The results
indicated that EASR could inhibit the secretion of HBsAg
and HBeAg dose dependently in HepG2 2.2.15 cells (P < .05;
Figure 2), and 3TC has little eﬀect on the HBeAg secretion.4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: The eﬀect of EASR on HBV DNA replication. Extracellu-
lar HBV DNA was isolated from the culture supernatant at 9 days
and quantiﬁed by real-time PCR. The results indicated that EASR
could inhibit HBV DNA replication dose dependently in vitro.T h e
data are presented as means ± SD (n = 3). ∗P < .05 as compared
with the no drug group.
EASR was more potent than 3TC for inhibiting the HBsAg
and HBeAg secreted by HepG2 2.2.15 cells.
To further conﬁrm the antiviral activity of EASR in
HepG2 2.2.15 cells, the extracellular HBV DNA levels were
evaluated by real-time PCR. Consistent with the inhibitory
eﬀects on HBsAg and HBeAg secretion, EASR treatment of
HepG2 2.2.15 cells at various concentrations resulted in the
reduction of the extracellular HBV DNA levels in a dose-
dependent manner (P < .05; Figure 3).
3.3.InductionofApoptosisbyEASR. Flowcytometricanalysis
was performed to assess the apoptosis of HepG2 2.2.15 cells
after 48h of exposure to EASR. As shown in Figure 4,t h e
percentageofapoptoticcellsincreasedsigniﬁcantlyfollowing
EASR treatment (P < .05).
3.4. Inhibition of HBV Promoter Activities by EASR. To
examine the eﬀect of EASR on HBV promoter activities, we
constructed ﬁve plasmids (pCp-Luc, pS1p-Luc, pS2p-Luc,
pXp-Luc and pFp-Luc) containing the diﬀerent promoter
regions of HBV followed by the luciferase reporter gene.
After transient transfection of these plasmids into HepG2
cells and EASR treatment, the viral promoter activities were
examinedbyaluciferasereporterassay. AsshowninFigure 5,
EASRinhibitedtheactivitiesofHBVpromoters(Cp,S1pand
Fp) in HepG2 cells signiﬁcantly (P < .05).
3.5. Inhibition of the p53 Signaling Pathway by EASR. To
determine the eﬀect of EASR on signaling pathway activities,
a series of plasmids containing the luciferase reporter gene
were transfected into HepG2 cells. After transfection, we
∗
0
5
10
15
20
25
30
35
A
p
o
p
t
o
s
i
s
(
%
)
Control EASR(40μg/mL)
Figure 4: The apoptosis of HepG2 2.2.15 cells after EASR
treatment. The results indicated that the percentage of apop-
totic cells increased signiﬁcantly following incubation with EASR
(40μgmL −1) for 48h. The data are presented as means ± SD (n =
3). ∗P < .05 as compared with the no drug group.
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Figure 5: The eﬀect of EASR on HBV transcription in vitro.T h e
plasmids of the ﬁve HBV promoters (Cp, S1p, S2p, Xp and Fp)
were transfected into HepG2 cells, respectively. In the experimental
group, cells were treated with 40μgmL −1 EASR for 48h. And
the control group was cultured without EASR treatment. HBV
promoter activities were then determined by luciferase reporter
assay. EASR selectively inhibited the activities of HBV promoters
(Cp, S1p and Fp) in HepG2 cells signiﬁcantly (P < .05). The data
are presented asmeans ±SD (n = 3). ∗P < .05 ascompared with the
control group.
examined the signaling pathway activities by luciferase assay.
As shown in Figure 6, EASR selectively inhibited the activity
of p53-associated signaling pathway signiﬁcantly (P < .05).
4.Discussion
Although several pharmacological strategies are currently
being implemented to treat aﬀected patients, no satisfactoryEvidence-Based Complementary and Alternative Medicine 5
antiviral therapy against HBV infection has yet been fully
developed. Thus, it has become urgent to ﬁnd new and
eﬀective anti-HBV drugs. Ampelopsis, a plant used in folk
medicine to treat liver disease, is widely distributed in
tropicalandsubtropicalregions[7].Theacti v eingr edientsof
Ampelopsis are mainly ﬂavonoids, such as ampelopsin, dihy-
dromyricetin, myricetin, and so forth [12]. The ﬂavonoids
have recently aroused considerable interest because of their
potential beneﬁcial eﬀects on human health; they have
been reported to have antiviral, anti-allergic, anti-platelet,
anti-inﬂammatory, antitumor and anti-oxidant activities
[13].
In the present study, we investigated the anti-HBV activ-
ity of EASR in stably HBV-transfected HepG2 2.2.15 cells,
which can continuously produce complete virion particles
of HBV and a high level of viral proteins [14]. We found
that EASR could decrease the extracellular HBV DNA levels
and the secretion of HBsAg and HBeAg in a dose-dependent
manner. These results demonstrated for the ﬁrst time that
EASR possesses potent inhibitory activity against HBV gene
expression and replication in vitro.A n d3 T Cw a sf o u n d
to have no obvious inhibitory eﬀects on HBeAg secretion.
The result was similar to those from other experiments
[15, 16]. HBeAg plays an important role in viral persistence,
and the presence of HBeAg in serum indicates active viral
replication in hepatocytes [17]. Several prospective studies
have uniformly shown that high HBeAg and HBV DNA
levels are associated with an increased risk of liver ﬁbrosis,
cirrhosis and HCC [18–20]. The HBV viral load is an useful
prognostic parameter to evaluate the extent of liver disease
in patients with chronic HBV infection [21]. To determine
whether EASR treatment could decrease the liver damage
resulting from HBV infection, further work is needed to
investigate the antiviral activity of EASR in vivo.
The precise modulation of HBV gene expression is
essential for replication of the virus, and the expression
of HBV is mainly regulated at the transcription initiation
level [22]. To identify whether the cis-element in HBV
genome is responsible for the anti-HBV activity of EASR, we
examined the eﬀect of EASR on the activities of ﬁve diﬀerent
HBV promoters: Cp, S1p, S2p, Xp and Fp. When linked to
luciferase reporter genes, the activity of the individual HBV
promoters was determined by transfection experiments.
Our studies revealed that EASR is a potent transcriptional
inhibitor of Cp, S1p and Fp, but has no eﬀect on S2p and
Xp activities in human hepatoma cells. Cp plays a central
role in HBV gene expression and replication, directing the
transcription of pregenomic RNA and precore mRNA [23].
The S1p is indispensable for the formation of the transcrip-
tion initiation complex [10]. The full-length promoter has
a whole region of the HBV genome (U95551, ayw subtype)
between nt 123 and 1875, covering the intact regions of
enhancer I, Xp, Cp and enhancer II [11]. These promoters
of HBV may act as molecular switches, determining the gene
activity. The suppression of these “switches” could further
inﬂuence the transcription and translation of HBV genome,
resulting in the overall inhibition of viral replication. Two
enhancers (Enhancers I and II) also play important roles in
the regulation of viral gene transcription [10]. Either of the
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Figure 6: The eﬀect of EASR on cell signaling pathway activity
in vitro. The HepG2 cells were transfected with various plasmids
provided by PathDetect Cis-/Trans-Reporting Systems. In the
experimental group, cells were treated with 40μgmL −1 EASR
for 48h. And the control group was cultured without EASR
treatment. The signaling pathway activities were determined by
luciferasereporter assay.EASR inhibited theactivity ofp53pathway
signiﬁcantly (P < .05). The data are presented as means ± SD (n =
3). ∗P < .05 as compared with the control group.
two enhancers could activate the HBV promoters in vitro
[24]. But exactly how EASR inhibits HBV viral Cp, S1p and
Fp activities is still unknown.
To further investigate the molecular mechanism of anti-
HBV activity of EASR, we examined the inﬂuence of EASR
on several well-deﬁned intracellular signaling pathways by
use of a luciferase reporter assay. A series of plasmids
containing the luciferase reporter gene were transfected
into human hepatoma cells to analyze the induction of
the intracellular signal pathways after EASR treatment. We
found EASR selectively inhibited the activity of the p53-
associated pathway. Previous studies have demonstrated
that p53 plays a pivotal role in the modulation of cell-
cycle arrest, cell diﬀerentiation and induction of apoptosis
[25–27]. p53 is also essential for a host’s antiviral innate
immune responses [28]. It has been reported to associate
with the replication of several viruses, but its role in antiviral
defense is conﬂicting. p53 enhances the replications of
adenovirus, cytomegalovirus, encephalomyocarditis virus,
human parainﬂuenza virus and respiratory syncytial virus,
but it limits herpes simplex virus, poliovirus, hepatitis C
virus and vesicular stomatitis virus replications [29–35].
p53 causes G1 phase cell-cycle arrest that protects cells
from virus-mediated cell death [31]. Down-regulatation of
p53 could result in a decrease in G1 arrest and induce
apoptosis, thereby limiting viral replication [29]. Our results
revealed that EASR could induce apoptosis via inhibitions
of p53 pathway. We propose that the eﬀect of p53 on viral
replication is also dependent on the replicative cycle of the
virus.6 Evidence-Based Complementary and Alternative Medicine
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Figure 7: EASR exerts anti-HBV eﬀects via inhibition of HBV
transcription and the p53-associated signaling pathway.
In conclusion, EASR could exert anti-HBV activity by
decreasing both the level of extracellular HBV DNA and
the secretion of HBsAg and HBeAg antigens. We also
found the antiviral activity of EASR is associated with
the in vitro inhibitions of HBV promoters (Cp, S1p and
Fp) and p53 pathway. These results indicate that EASR
exerts anti-HBV eﬀects via inhibition of HBV transcription
and the p53-associated signaling pathway (Figure 7). This
helps to elucidate the mechanism underlying the potential
therapeutic value of EASR.
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